VURAL, Ö. Et Al. 2023. Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy. GAZI MEDICAL JOURNAL , vol.34, no.4 , 414-418.

VURAL, Ö., YAZOL, M., TOPUZ TÜRKCAN, B., OKUR, A., BÖRCEK, A. Ö., PINARLI, F. G., ... KARADENİZ, C.(2023). Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy. GAZI MEDICAL JOURNAL , vol.34, no.4, 414-418.

VURAL, ÖZGE Et Al. "Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy," GAZI MEDICAL JOURNAL , vol.34, no.4, 414-418, 2023

VURAL, ÖZGE Et Al. "Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy." GAZI MEDICAL JOURNAL , vol.34, no.4, pp.414-418, 2023

VURAL, Ö. Et Al. (2023) . "Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy." GAZI MEDICAL JOURNAL , vol.34, no.4, pp.414-418.

@article{article, author={ÖZGE VURAL Et Al. }, title={Prognostic Factors for Survival in Pediatric Diffuse Midline Gliomas: The Importance of T2 FLAIR Missmatch Sign and Nimotuzumab Therapy}, journal={GAZI MEDICAL JOURNAL}, year=2023, pages={414-418} }